MDPI

The effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis, familial pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world study

Supplementary Materials

Table S1. Comparison of annual FVC and DLCO decline rate in the entire study population. *: paired comparison.

Parameters	Pre-treatment	12-months	24-months	36 months	48 months
N°		88	49	24	10
Δ FVC ml p-value mean difference (95% CI)	37 - 256 ± 352	-123.7 ± 297 p=0.0374* -133.1 (-258.4 to 7.803)	-156.7 ± 285.8 p=0.5589	-121.5 ± 254.7 p=0.6598	-164.7 ± 200 p=0.2259
ΔDLCO ml/min/mmHg p-value mean difference (95% CI)	-0.82 ± 1.75	-0.27 ± 1.6 p=0.0428* -0.55.1 (-1.87 to 0.30)	-0.3 ± 1.1 p=0.7812	-0.42 ± 0.9 p=0.8856	-0.51 ± 2.4 p=0.4967